W. Joseph Herring, MD, PhD, from Merck Sharp & Dohme in Whitehouse Station, NJ, and colleagues randomly assigned 254 healthy adults with primary insomnia to placebo or suvorexant (10mg, 20mg, 40mg ...

Merck Sharp & Dohme LLC has identified orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia and narcolepsy. BioWorld Science Neurology/psychiatric Patents Popular ...

Committee members deem newly developed selective antagonist of orexin receptors effective but expressed concern about somnolence and driving safety for higher doses. ... Merck Sharp & Dohme Corp.) ...

“If approved, it will be a new, first-in-class treatment for patients with insomnia,” Merck R&D head Peter Kim said in the statement. Analysts are circumspect about whether the drug’s unique angle on ...